Published in J Control Release on April 02, 2001
Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm (2008) 7.67
Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier. Polymers (Basel) (2011) 3.62
Targeted drug delivery to tumors: myths, reality and possibility. J Control Release (2011) 2.69
In vivo biodistribution and clearance studies using multimodal organically modified silica nanoparticles. ACS Nano (2010) 2.30
PEGylated PLGA nanoparticles for the improved delivery of doxorubicin. Nanomedicine (2009) 1.70
Controlled surface modification with poly(ethylene)glycol enhances diffusion of PLGA nanoparticles in human cervical mucus. Mol Pharm (2009) 1.59
Delivery of therapeutic proteins. J Pharm Sci (2010) 1.58
Drug release kinetics and transport mechanisms of non-degradable and degradable polymeric delivery systems. Expert Opin Drug Deliv (2010) 1.38
Drug transport to brain with targeted nanoparticles. NeuroRx (2005) 1.37
Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: current progress and advances. J Control Release (2014) 1.32
Polylactide-co-glycolide nanoparticles for controlled delivery of anticancer agents. Int J Nanomedicine (2011) 1.26
Preparation, characterization and in-vitro evaluation of sustained release protein-loaded nanoparticles based on biodegradable polymers. Int J Nanomedicine (2008) 1.20
Targeted Nanodelivery of Drugs and Diagnostics. Nano Today (2010) 1.18
Preparation and in vitro evaluation of doxorubicin-loaded Fe₃O₄ magnetic nanoparticles modified with biocompatible copolymers. Int J Nanomedicine (2012) 1.10
PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv Drug Deliv Rev (2015) 1.08
Nanoparticle-mediated local delivery of Methylprednisolone after spinal cord injury. Biomaterials (2009) 1.03
Controlled release of insulin from PLGA nanoparticles embedded within PVA hydrogels. J Mater Sci Mater Med (2007) 1.02
Microparticle surface modifications targeting dendritic cells for non-activating applications. Biomaterials (2012) 0.99
Concepts and practices used to develop functional PLGA-based nanoparticulate systems. Int J Nanomedicine (2013) 0.97
Temporal control over cellular targeting through hybridization of folate-targeted dendrimers and PEG-PLA nanoparticles. Biomacromolecules (2012) 0.94
In vitro and in vivo evaluation of folate receptor-targeting amphiphilic copolymer-modified liposomes loaded with docetaxel. Int J Nanomedicine (2011) 0.94
Third generation gold nanoplatform optimized for radiation therapy. Transl Cancer Res (2013) 0.92
Endostar-loaded PEG-PLGA nanoparticles: in vitro and in vivo evaluation. Int J Nanomedicine (2010) 0.92
Synthesis, characterization, and in vitro evaluation of novel polymer-coated magnetic nanoparticles for controlled delivery of doxorubicin. Nanotechnol Sci Appl (2012) 0.91
Poly(lactic-co-glycolic) acid-controlled-release systems: experimental and modeling insights. Crit Rev Ther Drug Carrier Syst (2013) 0.90
Development of multiple-layer polymeric particles for targeted and controlled drug delivery. Nanomedicine (2009) 0.88
Development of pH-sensitive insulin nanoparticles using Eudragit L100-55 and chitosan with different molecular weights. AAPS PharmSciTech (2010) 0.87
Development and characterization of nanoparticulate formulation of a water soluble prodrug of dexamethasone by HIP complexation. J Microencapsul (2010) 0.87
Light-activated, in situ forming gel for sustained suprachoroidal delivery of bevacizumab. Mol Pharm (2013) 0.86
Biodegradable mucus-penetrating nanoparticles composed of diblock copolymers of polyethylene glycol and poly(lactic-co-glycolic acid). Drug Deliv Transl Res (2012) 0.86
Prolonged blood circulation and enhanced tumor accumulation of folate-targeted dendrimer-polymer hybrid nanoparticles. J Control Release (2014) 0.85
Polymeric nanoparticles for pulmonary protein and DNA delivery. Acta Biomater (2014) 0.85
A physiologically based pharmacokinetic model for ionic silver and silver nanoparticles. Int J Nanomedicine (2013) 0.85
Synthesis route and three different core-shell impacts on magnetic characterization of gadolinium oxide-based nanoparticles as new contrast agents for molecular magnetic resonance imaging. Nanoscale Res Lett (2012) 0.85
Rational development of a cytotoxic peptide to trigger cell death. Mol Pharm (2012) 0.84
Adriamycin release from poly(lactide-coglycolide)-polyethylene glycol nanoparticles: synthesis, and in vitro characterization. Int J Nanomedicine (2006) 0.83
Smart Nanoparticles for Drug Delivery: Boundaries and Opportunities. Chem Eng Sci (2015) 0.83
Ligand-decorated nanogels: fast one-pot synthesis and cellular targeting. Biomacromolecules (2012) 0.83
Cellular delivery of PEGylated PLGA nanoparticles. J Pharm Pharmacol (2011) 0.83
In vivo half life of nanoencapsulated L-asparaginase. J Mater Sci Mater Med (2002) 0.82
Gemcitabine-loaded PLGA-PEG immunonanoparticles for targeted chemotherapy of pancreatic cancer. Cancer Nanotechnol (2013) 0.82
Spatiotemporal release of BMP-2 and VEGF enhances osteogenic and vasculogenic differentiation of human mesenchymal stem cells and endothelial colony-forming cells co-encapsulated in a patterned hydrogel. J Control Release (2015) 0.79
Comparison of doxorubicin anticancer drug loading on different metal oxide nanoparticles. Medicine (Baltimore) (2015) 0.78
Heterogeneity in nanoparticles influences biodistribution and targeting. Nanomedicine (Lond) (2013) 0.78
Folate-modified lipid-polymer hybrid nanoparticles for targeted paclitaxel delivery. Int J Nanomedicine (2015) 0.77
Size reproducibility of gadolinium oxide based nanomagnetic particles for cellular magnetic resonance imaging: effects of functionalization, chemisorption and reaction conditions. Iran J Pharm Res (2015) 0.77
Formulation of diblock polymeric nanoparticles through nanoprecipitation technique. J Vis Exp (2011) 0.77
PLGA nanoparticles for peptide receptor radionuclide therapy of neuroendocrine tumors: a novel approach towards reduction of renal radiation dose. PLoS One (2012) 0.77
In vitro and ex vivo evaluations on transdermal delivery of the HIV inhibitor IQP-0410. PLoS One (2013) 0.77
Nanogel-crosslinked nanoparticles increase the inhibitory effects of W9 synthetic peptide on bone loss in a murine bone resorption model. Int J Nanomedicine (2015) 0.77
Direct Observation of Early-Stage High-Dose Radiotherapy-Induced Vascular Injury via Basement Membrane-Targeting Nanoparticles. Small (2015) 0.76
Biosafe nanoscale pharmaceutical adjuvant materials. J Biomed Nanotechnol (2014) 0.76
Efficient drug delivery and induction of apoptosis in colorectal tumors using a death receptor 5-targeted nanomedicine. Mol Ther (2014) 0.76
Inhaled sildenafil as an alternative to oral sildenafil in the treatment of pulmonary arterial hypertension (PAH). J Control Release (2017) 0.75
Exploiting the tumor phenotype using biodegradable submicron carriers of chemotherapeutic drugs. Crit Rev Oncog (2014) 0.75
A novel double-targeted nondrug delivery system for targeting cancer stem cells. Int J Nanomedicine (2016) 0.75
Long-term effect of ropivacaine nanoparticles for sciatic nerve block on postoperative pain in rats. Int J Nanomedicine (2016) 0.75
Synthesis and functionalization of protease-activated nanoparticles with tissue plasminogen activator peptides as targeting moiety and diagnostic tool for pancreatic cancer. J Nanobiotechnology (2016) 0.75
Long-circulating Janus nanoparticles made by electrohydrodynamic co-jetting for systemic drug delivery applications. J Drug Target (2015) 0.75
Current and emerging formulation strategies for the effective transdermal delivery of HIV inhibitors. Ther Deliv (2015) 0.75
Recovery of Drug Delivery Nanoparticles from Human Plasma Using an Electrokinetic Platform Technology. Small (2015) 0.75
Synthesis, characterization, and in vitro activity against Candida spp. of fluconazole encapsulated on cationic and conventional nanoparticles of poly(lactic-co-glycolic acid). Nanotechnol Sci Appl (2017) 0.75
Dual-Drug Containing Core-Shell Nanoparticles for Lung Cancer Therapy. Sci Rep (2017) 0.75
The sequence of the human genome. Science (2001) 101.55
The genome sequence of Drosophila melanogaster. Science (2000) 74.32
Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. Proc Natl Acad Sci U S A (1998) 39.20
Involvement of chemokine receptors in breast cancer metastasis. Nature (2001) 26.07
SPIDER and WEB: processing and visualization of images in 3D electron microscopy and related fields. J Struct Biol (1996) 22.89
A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell (2000) 17.61
A general approach to single-nucleotide polymorphism discovery. Nat Genet (1999) 13.39
Tetrahymena histone acetyltransferase A: a homolog to yeast Gcn5p linking histone acetylation to gene activation. Cell (1996) 9.86
The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci U S A (1998) 9.32
Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet (2000) 8.58
Recombination within natural populations of pathogenic bacteria: short-term empirical estimates and long-term phylogenetic consequences. Proc Natl Acad Sci U S A (2001) 7.90
IkappaB kinase-beta: NF-kappaB activation and complex formation with IkappaB kinase-alpha and NIK. Science (1997) 7.57
Identification and characterization of an IkappaB kinase. Cell (1997) 6.71
Nomenclature of major antimicrobial-resistant clones of Streptococcus pneumoniae defined by the pneumococcal molecular epidemiology network. J Clin Microbiol (2001) 6.66
Prevalence of specific language impairment in kindergarten children. J Speech Lang Hear Res (1997) 6.37
Quantum-dot-tagged microbeads for multiplexed optical coding of biomolecules. Nat Biotechnol (2001) 6.30
Steroid receptor coactivator-1 is a histone acetyltransferase. Nature (1997) 6.15
Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene (2006) 5.86
Horizontal transfer of multiple penicillin-binding protein genes, and capsular biosynthetic genes, in natural populations of Streptococcus pneumoniae. Mol Microbiol (1991) 5.45
Geometric and electronic structure/function correlations in non-heme iron enzymes. Chem Rev (2000) 5.44
The DNA replication and damage checkpoint pathways induce transcription by inhibition of the Crt1 repressor. Cell (1998) 5.37
IRAK: a kinase associated with the interleukin-1 receptor. Science (1996) 5.32
Histone-like TAFs within the PCAF histone acetylase complex. Cell (1998) 5.26
The SAD1/RAD53 protein kinase controls multiple checkpoints and DNA damage-induced transcription in yeast. Genes Dev (1994) 5.20
Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase. Science (1996) 5.08
Arrhythmogenesis and contractile dysfunction in heart failure: Roles of sodium-calcium exchange, inward rectifier potassium current, and residual beta-adrenergic responsiveness. Circ Res (2001) 5.08
Negative regulation of Gcn4 and Msn2 transcription factors by Srb10 cyclin-dependent kinase. Genes Dev (2001) 4.91
DNA polymerase epsilon links the DNA replication machinery to the S phase checkpoint. Cell (1995) 4.90
Molecular cloning and functional analysis of a novel macrolide-resistance determinant, mefA, from Streptococcus pyogenes. Mol Microbiol (1996) 4.86
Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood (1997) 4.78
Cytochrome c release and apoptosis induced by mitochondrial targeting of nuclear orphan receptor TR3. Science (2000) 4.57
Embryonic lethality and vascular defects in mice lacking the Notch ligand Jagged1. Hum Mol Genet (1999) 4.55
The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM. Nature (1998) 4.47
mefE is necessary for the erythromycin-resistant M phenotype in Streptococcus pneumoniae. Antimicrob Agents Chemother (1997) 4.38
Effect of local medical opinion leaders on quality of care for acute myocardial infarction: a randomized controlled trial. JAMA (1998) 4.36
Diagnostic risk adjustment for Medicaid: the disability payment system. Health Care Financ Rev (1996) 4.34
A controlled study of adenoviral-vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis. N Engl J Med (1995) 4.30
Histone acetyltransferase activity of yeast Gcn5p is required for the activation of target genes in vivo. Genes Dev (1998) 4.23
Infectivity, transmission, and pathology of human-isolated H7N9 influenza virus in ferrets and pigs. Science (2013) 4.17
Identification of mutations in the COL4A5 collagen gene in Alport syndrome. Science (1990) 4.15
Fractional SR Ca release is regulated by trigger Ca and SR Ca content in cardiac myocytes. Am J Physiol (1995) 4.15
Evolutionary analyses of the human genome. Nature (2001) 4.13
Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res (1995) 4.11
DNA repair protein Ku80 suppresses chromosomal aberrations and malignant transformation. Nature (2000) 4.10
Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with In vitro and In vivo chemoresponses. Blood (1998) 4.07
Crystal structure of four-stranded Oxytricha telomeric DNA. Nature (1992) 3.96
Response to RAG-mediated VDJ cleavage by NBS1 and gamma-H2AX. Science (2000) 3.95
Pre-mRNA splicing and mRNA export linked by direct interactions between UAP56 and Aly. Nature (2001) 3.94
Aromatic hydrogen bond in sequence-specific protein DNA recognition. Nat Struct Biol (1996) 3.91
Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci U S A (1998) 3.89
Evaluation of PCR-generated chimeras, mutations, and heteroduplexes with 16S rRNA gene-based cloning. Appl Environ Microbiol (2001) 3.76
Translocation (8;21) in oligoblastic leukemia: is this a true myelodysplastic syndrome? Leuk Res (1994) 3.66
Effectiveness of community health workers in the care of persons with diabetes. Diabet Med (2006) 3.66
Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11S proteasome recruitment, and As2O3-induced PML or PML/retinoic acid receptor alpha degradation. J Exp Med (2001) 3.62
Liposome-mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Nat Med (1995) 3.61
PKD1 interacts with PKD2 through a probable coiled-coil domain. Nat Genet (1997) 3.58
Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood (1997) 3.56
A model of protein synthesis based on cryo-electron microscopy of the E. coli ribosome. Nature (1995) 3.56
A presynaptic inositol-5-phosphatase. Nature (1996) 3.54
HLA and AIDS: a cautionary tale. Trends Mol Med (2001) 3.51
Identity between TRAP and SMCC complexes indicates novel pathways for the function of nuclear receptors and diverse mammalian activators. Mol Cell (1999) 3.47
Concerted dephosphorylation of the transcription factor NFAT1 induces a conformational switch that regulates transcriptional activity. Mol Cell (2000) 3.44
Role of interspecies transfer of chromosomal genes in the evolution of penicillin resistance in pathogenic and commensal Neisseria species. J Mol Evol (1992) 3.44
Phosphorylation of the AMPA receptor subunit GluR2 differentially regulates its interaction with PDZ domain-containing proteins. J Neurosci (2000) 3.44
State estimates of Medicaid expenditures attributable to cigarette smoking, fiscal year 1993. Public Health Rep (1998) 3.41
Effect of mutations in genes affecting homologous recombination on restriction enzyme-mediated and illegitimate recombination in Saccharomyces cerevisiae. Mol Cell Biol (1994) 3.41
Three-dimensional structure of an evolutionarily conserved N-terminal domain of syntaxin 1A. Cell (1998) 3.40
Myocardial ischemia and reperfusion: a murine model. Am J Physiol (1995) 3.38
Development and evaluation of functional gene arrays for detection of selected genes in the environment. Appl Environ Microbiol (2001) 3.36
Upregulation of Na(+)/Ca(2+) exchanger expression and function in an arrhythmogenic rabbit model of heart failure. Circ Res (1999) 3.35
Clustering of AMPA receptors by the synaptic PDZ domain-containing protein PICK1. Neuron (1999) 3.33
Conversion of diploidy to haploidy. Nature (2000) 3.28
Homocysteine-induced endoplasmic reticulum stress causes dysregulation of the cholesterol and triglyceride biosynthetic pathways. J Clin Invest (2001) 3.24
Mammalian Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway. Oncogene (1999) 3.23
ESA1 is a histone acetyltransferase that is essential for growth in yeast. Proc Natl Acad Sci U S A (1998) 3.19
Expression of bbc3, a pro-apoptotic BH3-only gene, is regulated by diverse cell death and survival signals. Proc Natl Acad Sci U S A (2001) 3.16
A herpesvirus of rhesus monkeys related to the human Kaposi's sarcoma-associated herpesvirus. J Virol (1997) 3.10
Real time detection of DNA.RNA hybridization in living cells. Proc Natl Acad Sci U S A (1998) 3.10
Isolation, characterization, and distribution of denitrifying toluene degraders from a variety of habitats. Appl Environ Microbiol (1994) 3.09
Perinatal lethality with kidney and pancreas defects in mice with a targetted Pkd1 mutation. Nat Genet (1997) 3.06
Mutations in the laminin alpha 2-chain gene (LAMA2) cause merosin-deficient congenital muscular dystrophy. Nat Genet (1995) 3.05
The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2',3'-dideoxy-3'-thiacytidine. Antimicrob Agents Chemother (1993) 3.00
Timetables of neurogenesis in the human brain based on experimentally determined patterns in the rat. Neurotoxicology (1993) 3.00
Histone chaperone Asf1 is required for histone H3 lysine 56 acetylation, a modification associated with S phase in mitosis and meiosis. Proc Natl Acad Sci U S A (2006) 2.98
Human magnetic resonance imaging at 8 T. NMR Biomed (1998) 2.96
A primitive enantiornithine bird and the origin of feathers. Science (2000) 2.96
ORegAnno: an open access database and curation system for literature-derived promoters, transcription factor binding sites and regulatory variation. Bioinformatics (2006) 2.93
A(2A) adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice. J Neurosci (1999) 2.92
Identification of a translation initiation factor 3 (eIF3) core complex, conserved in yeast and mammals, that interacts with eIF5. Mol Cell Biol (1998) 2.91
Rocuronium (Org 9426) for caesarean section. Br J Anaesth (1994) 2.86
Therapeutic benefit of intracerebral transplantation of bone marrow stromal cells after cerebral ischemia in rats. J Neurol Sci (2001) 2.84
Interfacial catalysis: the mechanism of phospholipase A2. Science (1990) 2.84
Search for a resonance decaying into WZ boson pairs in pp collisions. Phys Rev Lett (2010) 2.83
Basal cell carcinomas in mice overexpressing Gli2 in skin. Nat Genet (2000) 2.82
DNA damage and cell cycle regulation of ribonucleotide reductase. Bioessays (1993) 2.81
Genome-wide expression profiling of human blood reveals biomarkers for Huntington's disease. Proc Natl Acad Sci U S A (2005) 2.75
Dentinogenesis imperfecta 1 with or without progressive hearing loss is associated with distinct mutations in DSPP. Nat Genet (2001) 2.75